NUVB
Nuvation Bio Inc.
$4.57
-2.77%
2026-10-23
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Key Fundamentals
Forward P/E
-382.67
EPS (TTM)
$-0.44
ROE
-47.8%
Revenue Growth (YoY)
555.6%
Profit Margin
-88.2%
Debt/Equity
163.97
Price/Book
7.91
Beta
1.53
Market Cap
$2.02B
Avg Volume (10D)
5.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$7.58
60D Low
$4.34
Avg Volume
5.4M
Latest Close
$4.57
Get breakout alerts for NUVB
Sign up for Breakout Scanner to receive daily notifications when NUVB triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Nuvation Bio Inc. (NUVB) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors NUVB daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NUVB operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.